Skip to main content
Top
Published in: Rheumatology International 3/2012

01-03-2012 | Original Article

Clinical and demographic characteristics of patients with psoriatic arthritis in northern Israel

Authors: Devy Zisman, Lihi Eder, Muna Elias, Arie Laor, Haim Bitterman, Michael Rozenbaum, Joy Feld, Doron Rimar, Itzhak Rosner

Published in: Rheumatology International | Issue 3/2012

Login to get access

Abstract

Disease patterns and manifestations may vary among different populations and change over time. The purpose of our study was to define the demographic, clinical, roentgenologic, and laboratory findings in a recent cohort of psoriatic arthritis patients followed up in rheumatology clinics in northern Israel. We conducted a cross-sectional study of 149 psoriatic arthritis patients. Demographic, clinical, laboratory, and radiological data, with emphasis on the pattern of arthritis, treatment regimens, and co-morbidities were obtained from patient interviews and rheumatology file reviews. The mean age of our patients was 58.2, with a female preponderance (57.3%). Skin involvement preceded the arthritis or was diagnosed simultaneously in 90.1% of cases. The most common joint involvement was an RA-like arthritis (49.7% of the patients) correlating positively with age, female gender, and disease duration. Dactylitis and nail involvement were observed in 33.6 and 36.2% of the patients, respectively. Radiographic bone erosions were noted in a third of the patients, correlating with DIP and RA-like arthritis patterns. Most patients were treated with methotrexate (73.8%) and a combination therapy (41.4%). An increased incidence of hypertension, hyperlipidemia, and diabetes mellitus was noted in our cohort compared to the general Israeli population. Our survey, the first of its kind conducted in Israel, noted a relative increase in the polyarticular manifestation of PsA and a decrease in spondyloarthropathy, compared to historic series, with more aggressive disease found in women above the age of sixty. These findings are in line with recent surveys.
Literature
1.
go back to reference Brockbank J, Gladman DD (2002) Diagnosis and management of psoriatic arthritis. Drugs 62:2447–2457PubMedCrossRef Brockbank J, Gladman DD (2002) Diagnosis and management of psoriatic arthritis. Drugs 62:2447–2457PubMedCrossRef
2.
go back to reference Brockbank J, Gladman DD (2002) Diagnosis and management of psoriatic arthritis. Drugs 62:2447–2457PubMedCrossRef Brockbank J, Gladman DD (2002) Diagnosis and management of psoriatic arthritis. Drugs 62:2447–2457PubMedCrossRef
3.
go back to reference Taylor W, Gladman DD, Helliwell P et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673PubMedCrossRef Taylor W, Gladman DD, Helliwell P et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673PubMedCrossRef
4.
go back to reference Zachariae H (2003) Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 4:441–447PubMedCrossRef Zachariae H (2003) Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 4:441–447PubMedCrossRef
5.
go back to reference Gladman DD, Shuckett R, Russell ML et al (1987) Psoriatic arthritis. An analysis of 220 patients. Q J Med 62:127–141PubMed Gladman DD, Shuckett R, Russell ML et al (1987) Psoriatic arthritis. An analysis of 220 patients. Q J Med 62:127–141PubMed
6.
go back to reference Jones SM, Armas JB, Cohen MG, Lovell CR, Evison G, McHugh NJ (1994) Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 33:834–839PubMedCrossRef Jones SM, Armas JB, Cohen MG, Lovell CR, Evison G, McHugh NJ (1994) Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 33:834–839PubMedCrossRef
8.
go back to reference Khan M, Schentag C, Gladman DD (2003) Clinical and radiological changes during psoriatic arthritis disease progression. J Rheumatol 30:1022–1026PubMed Khan M, Schentag C, Gladman DD (2003) Clinical and radiological changes during psoriatic arthritis disease progression. J Rheumatol 30:1022–1026PubMed
9.
go back to reference Veale D, Rogers S, Fitzgerald O (1994) Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 33:133–138PubMedCrossRef Veale D, Rogers S, Fitzgerald O (1994) Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 33:133–138PubMedCrossRef
10.
go back to reference Cuellar ML, Citera G, Espinoza LR (1994) Treatment of psoriatic arthritis. Baillieres Clin Rheumatol 8:483–498PubMedCrossRef Cuellar ML, Citera G, Espinoza LR (1994) Treatment of psoriatic arthritis. Baillieres Clin Rheumatol 8:483–498PubMedCrossRef
11.
go back to reference Abu-Shakra M, Gladman DD, Thorne CT et al (1995) Long term methotrexate therapy in psoriatic arthritis: clinical and radiologic outcome. J Rheumatol 22:241–245PubMed Abu-Shakra M, Gladman DD, Thorne CT et al (1995) Long term methotrexate therapy in psoriatic arthritis: clinical and radiologic outcome. J Rheumatol 22:241–245PubMed
12.
go back to reference Gupta AK, Grober JS, Hamilton TA et al (1995) Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 22:894–898PubMed Gupta AK, Grober JS, Hamilton TA et al (1995) Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 22:894–898PubMed
13.
go back to reference Kaltwasser JP, Nash P, Gladman D et al (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50:1939–1950PubMedCrossRef Kaltwasser JP, Nash P, Gladman D et al (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50:1939–1950PubMedCrossRef
14.
go back to reference Salvarani C, Maccioni P, Olivieri I et al (2001) A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 28:2274–2282PubMed Salvarani C, Maccioni P, Olivieri I et al (2001) A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 28:2274–2282PubMed
15.
go back to reference Mease PJ, Goffe BS, Metz J et al (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial. Lancet 356:385–390PubMedCrossRef Mease PJ, Goffe BS, Metz J et al (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial. Lancet 356:385–390PubMedCrossRef
16.
go back to reference Salvarani C, Cantini F, Olivieri I et al (2003) Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum 49:541–545PubMedCrossRef Salvarani C, Cantini F, Olivieri I et al (2003) Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum 49:541–545PubMedCrossRef
17.
go back to reference Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM et al (1991) Psoriatic arthritis: a clinical, immunological and radiological study of 180 patients. British J Rheumatol 30:245–250CrossRef Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM et al (1991) Psoriatic arthritis: a clinical, immunological and radiological study of 180 patients. British J Rheumatol 30:245–250CrossRef
18.
go back to reference Rajendran JP, Ledge SG, Rani K et al (2003) Psoriatic arthritis. J Assoc Physicians India 51:1065–1068PubMed Rajendran JP, Ledge SG, Rani K et al (2003) Psoriatic arthritis. J Assoc Physicians India 51:1065–1068PubMed
19.
go back to reference Madland TM, Apalset EM, Johannessen AE, Rossebo B, Brun JG (2005) Prevalence, disease manifestations and treatment of psoriatic arthritis in western Norway. J Rheumatol 32:1918–1922PubMed Madland TM, Apalset EM, Johannessen AE, Rossebo B, Brun JG (2005) Prevalence, disease manifestations and treatment of psoriatic arthritis in western Norway. J Rheumatol 32:1918–1922PubMed
20.
go back to reference Punzi L, Pianon M, Rossini P et al (1999) Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease. Ann Rheum Dis 58:226–229PubMedCrossRef Punzi L, Pianon M, Rossini P et al (1999) Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease. Ann Rheum Dis 58:226–229PubMedCrossRef
21.
go back to reference Williamson L, Dalbeth N, Dockerty JL et al (2004) Extended report: Nail disease in psoriatic arthritis—clinically important, potentially treatable and often overlooked. Rheumtology (Oxford) 43:690–691CrossRef Williamson L, Dalbeth N, Dockerty JL et al (2004) Extended report: Nail disease in psoriatic arthritis—clinically important, potentially treatable and often overlooked. Rheumtology (Oxford) 43:690–691CrossRef
22.
go back to reference Sampaio-Barros PD, Conde RA, Bonfiglioli R et al (2006) Characterization of outcome of uveitis in 350 patients with spondyloarthropathies. Rheumatol Int 26:1143–1146PubMedCrossRef Sampaio-Barros PD, Conde RA, Bonfiglioli R et al (2006) Characterization of outcome of uveitis in 350 patients with spondyloarthropathies. Rheumatol Int 26:1143–1146PubMedCrossRef
23.
go back to reference Soriano ER, McHugh NJ (2006) Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 33:1422–1430PubMed Soriano ER, McHugh NJ (2006) Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 33:1422–1430PubMed
24.
go back to reference Jones G, Crotty M, Brooks P (2000) Interventions for psoriatic arthritis. Cochrane Database Syst Rev 3:CD000212 Jones G, Crotty M, Brooks P (2000) Interventions for psoriatic arthritis. Cochrane Database Syst Rev 3:CD000212
25.
go back to reference Kimhi O, Caspi D, Bornstein NM et al (2007) Prevalence and risk factors for atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 36:203–209PubMedCrossRef Kimhi O, Caspi D, Bornstein NM et al (2007) Prevalence and risk factors for atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 36:203–209PubMedCrossRef
26.
go back to reference Han C, Robinson DW Jr, Hackett MV et al (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. J Rheumatol 33:2167–2172PubMed Han C, Robinson DW Jr, Hackett MV et al (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. J Rheumatol 33:2167–2172PubMed
27.
go back to reference Eder L, Zisman D, Barzilai M, Laor A, Rahat M, Rozenbaum M, Bitterman H, Feld J, Rimar D, Rosner I (2008) Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol 35:877–882PubMed Eder L, Zisman D, Barzilai M, Laor A, Rahat M, Rozenbaum M, Bitterman H, Feld J, Rimar D, Rosner I (2008) Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol 35:877–882PubMed
28.
go back to reference Rennert G, Peterburg Y (2001) Prevalence of selected chronic diseases in Israel. Isr Med Assoc J 3:404–408PubMed Rennert G, Peterburg Y (2001) Prevalence of selected chronic diseases in Israel. Isr Med Assoc J 3:404–408PubMed
Metadata
Title
Clinical and demographic characteristics of patients with psoriatic arthritis in northern Israel
Authors
Devy Zisman
Lihi Eder
Muna Elias
Arie Laor
Haim Bitterman
Michael Rozenbaum
Joy Feld
Doron Rimar
Itzhak Rosner
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 3/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1673-1

Other articles of this Issue 3/2012

Rheumatology International 3/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.